Lincoln Pharmaceuticals: Certificate for Quarter Ended June 30, 2026 Under SEBI Regs
Lincoln Pharmaceuticals Limited received a confirmation certificate from its RTA, MUFG Intime India Private Limited, for the quarter ended June 30, 2026. The certificate confirms the processing of dematerialisation requests as per SEBI regulations.
This is a standard compliance filing and does not involve any new financial information or strategic changes that would significantly impact the company.
The announcement is a routine regulatory filing and does not contain any information that would positively or negatively impact the company's stock.
Lincoln Pharmaceuticals Limited has submitted a confirmation certificate for the quarter ended June 30, 2026, as required by Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
This certificate has been received from M/s. MUFG Intime India Private Limited, the company's Registrar & Share Transfer Agent (RTA). The RTA confirms that securities received for dematerialisation during the quarter were processed and that the associated certificates were either accepted or rejected by the depositories. Furthermore, the RTA confirmed that the security certificates received were duly verified, mutilated, and cancelled, with the depositories' names substituted in the register of members within the prescribed timelines.
The company has requested that this information be taken on record.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.